Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (91)

« Back to Publications

Securing the future of immunisation: ESCMID’s vision

Ramasamy MN. et al, (2026), CMI Communications, 3, 105167 - 105167

Enablers and barriers to participation in vaccine trials: a narrative synthesis.

Daniel N. et al, (2026), Vaccine, 73

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

Securing the future of immunisation: ESCMID's vision.

Ramasamy MN. et al, (2025), Clin Microbiol Infect

Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

Gbesemete D. et al, (2025), Lancet Microbe, 6

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).

Macedo BRD. et al, (2025), BMJ Open, 15

Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.

McCann N. et al, (2025), N Engl J Med, 393, 1704 - 1714

Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.

Hanumunthadu B. et al, (2025), EBioMedicine, 119

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Understanding gender dynamics, consent experiences, and community engagement in clinical trials in the context of a Lassa fever vaccine trial in Ghana

Afari-Asiedu S. et al, (2025), Journal of Interventional Epidemiology and Public Health, 8

Vaccines against Lassa fever virus (VITAL): Phase 1 safety and immunogenicity studies of a Lassa fever vaccine, ChAdOx1 LassaJ, in healthy volunteers in the UK and Ghana

Curtis BI. et al, (2025), Journal of Interventional Epidemiology and Public Health, 8

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

HORBY P. et al, (2025), The Lancet Infectious Diseases

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

HORBY PW. et al, (2025), The Lancet Infectious Diseases

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

HAYNES R. et al, (2025), EClinicalMedicine

Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol.

Brito-Mutunayagam S. et al, (2025), PLoS One, 20

Load More

1
2
3
4
5
6
7